Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Sanofi

France warns US buyer of Sanofi division of penalties for shifting production abroad

Private equity firm CD&R revealed to be in exclusive talks to buy 50% stake in consumer healthcare arm Opella

The Guardian - UK

Sanofi Pursues Sale Of Painkiller After Political Controversy

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy.

International Business Times

‘The UK is at the back of the race of turtles’: Sanofi’s boss on the need to develop new medicines

Paul Hudson, the Briton in charge of the French drug firm, is a big believer in the potential of AI to transform healthcare

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

France could block sale of 'best-selling' drug if production doesn't stay local

France’s Economy Minister has warned that the government could block the sale of a subsidiary of the French pharmaceutical company Sanofi to a US private equity firm if it cannot guarantee that its production of paracetamol, under the name Doliprane, remains in France.

Radio France Internationale

Painkiller Sale Plan To US Gives France Major Headache

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry against the project from politicians on all sides.

International Business Times

Pharmaceutical giant Sanofi looks to sell consumer health unit, sparks political uproar

France's Economy and Industry ministers, Antoine Armand and Marc Ferracci, are heading to Lisieux this Monday to visit the production sites of popular headache reliever Doliprane. The visit takes place after the maker of the pill, French pharma group Sanofi, said it was in talks to sell off its consumer…

France 24

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Your gas stove might be making your asthma worse. Here’s what you can do about it

We may think of air pollution as an outdoor problem, made up of car exhaust and smog. But if the air inside our homes is polluted, this can also affect our health.

The Conversation

Older adults 65+ should get flu shots earlier in the season. Here’s why they also need stronger vaccines

Two flu vaccines are FDA-approved exclusively for people 65 and older, who are at higher risk of severe infection.

Fortune

New RSV vaccine rolled out in London after virus hospitalised thousands in capital in a year

Officials say vaccination programme could prevent thousands of hospital admissions for babies

Evening Standard

Shanghai Composite Index Fell 0.5% on Thursday

Shenzhen Component Index closed up 0.94%

Caixin Global

Dr. Reddy's Strategic Vision Reiterated Following Strong Q1FY25 Results

Dr. Reddy's reported consolidated revenues of ₹7,673 crores (US$ 921 million) for Q1FY25, marking a 14% year-on-year increase and a 8% sequential growth.

International Business Times

Shanghai Composite Index Fell 0.4% on Wednesday

Shenzhen Component Index closed down 0.31%

Caixin Global

3 Gene-Editing Stocks to Buy for Future Health Advances

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Blue-Chip Stocks With Strong Buy Ratings

Blue-chip stocks offer stability and consistent growth irrespective of market conditions. Thus, blue chip names Lockheed Martin (LMT), Regeneron Pharmaceuticals (REGN), and Cigna Group (CI) could be prudent additions to your portfolios. These stocks are Strong Buy-rated in our proprietary POWR Ratings system. Read on.

International Business Times

From Ice Baths To Osteopaths: Unproven Therapies At The Olympics

The Paris Olympics have been a showcase not only for athletic prowess but also for therapies such as ice baths and osteopathy which have little scientifically proven medical value, according to experts.

StockNews.com

3 Biotech Stocks With Revolutionary Pipelines to Buy Today

The biotech industry is experiencing rapid growth owing to new drug innovations and advancements in healthcare. To capitalize on the industry's expansion, it could be wise to invest in solid biotech stocks, Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD), which have revolutionary pipelines. Read on….

Fortune

Are these the most corporate Olympics ever?

It’s rather exceptional that a G7 Olympic host gets the support of so many of its largest companies.

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

Can I take antihistamines everyday? More than the recommended dose? What if I’m pregnant? Here’s what the research says

Allergies happen when your immune system overreacts to a normally harmless substance like dust or pollen. Hay fever, hives and anaphylaxis are all types of allergic reactions.

Fortune

The secrets of success with Paul Hudson, CEO of Sanofi

Today we meet with British CEO Paul Hudson to find out how he plans to build the Sanofi of tomorrow.

Fortune

Usher and Apple CEO Tim Cook had a meeting. Now the Super Bowl performer is taking his ideas to Capitol Hill

Usher will join French pharma giant Sanofi in Washington, D.C., to discuss the importance of early screening for type 1 diabetes.

Fortune

Sanofi’s CEO thinks OpenAI offers 'insane' potential for the pharmaceutical industry

Sanofi CEO Paul Hudson thinks AI offers 'insane' potential for the pharmaceutical industry, which can spend up to $4 billion developing a drug.

International Business Times

Sanofi Allies With OpenAI, Formation Bio For AI Use In Drug Development

French pharmaceutical company Sanofi announced Tuesday a partnership with ChatGPT-founder OpenAI and US biotech firm Formation Bio to accelerate the use of artificial intelligence in developing drugs.

The Guardian - UK

‘The issue is when to pull the trigger’: how prepared are we for human bird flu?

The H5N1 virus has been devastating bird populations, and is now infecting mammals too. Is human-to-human transmission next? And are we ready for another pandemic?

Kiplinger

Stock Market Today: Stocks End Mixed on the Day, Higher on the Week

The latest consumer sentiment data showed inflation concerns are on the rise.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.